Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Buy of Genzyme Genetics Clears FTC

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that its $925 million proposed acquisition of Genzyme Genetics has cleared antitrust review.

The Burlington, N.C.-based medical laboratory testing and services firm said that it has received early termination from the Federal Trade Commission of the waiting period under the federal Hart-Scott-Rodino Antitrust Improvement Act of 1976, clearing one hurdle for LabCorp to close the purchase of Genzyme Genetics on or around Dec. 1.

The deal is expected to have a net cash cost to LabCorp of about $795 million, after income tax benefits and acquisition-related costs have been factored in.

Genyzme Genetics, a business unit of Genzyme, performs more than 1.5 million clinical tests each year. In 2009, it generated about $371 million in revenues. The menu of services it provides includes maternal serum screening, prenatal diagnostics, carrier screening, and postnatal testing.

The sale of the business is part of a strategy by Genzyme to concentrate on its core business.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.